4.7 Review

Third-line therapy for chronic myeloid leukemia: current status and future directions

期刊

JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 14, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s13045-021-01055-9

关键词

Chronic myeloid leukemia; Third line; Tyrosine kinase inhibitors; Emerging therapies

资金

  1. Novartis

向作者/读者索取更多资源

CML is driven by the BCR-ABL1 fusion protein, making the ATP binding site of ABL1 an optimal target for TKIs. Despite improvements in prognosis, patients often fail treatment and require new therapeutic options.
Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome. The BCR-ABL1 fusion protein is an optimal target for tyrosine kinase inhibitors (TKIs) that aim for the adenosine triphosphate (ATP) binding site of ABL1. While these drugs have greatly improved the prognosis for CML, many patients ultimately fail treatment, some requiring multiple lines of TKI therapy. Mutations can occur in the ATP binding site of ABL1, causing resistance by preventing the binding of many of these drugs and leaving patients with limited treatment options. The approved TKIs are also associated with adverse effects that may lead to treatment discontinuation in some patients. Efficacy decreases with each progressive line of therapy; data suggest little clinical benefit of treatment with a third-line (3L), second-generation tyrosine kinase inhibitor (2GTKI) after failure of a first-generation TKI and a 2GTKI. Novel treatment options are needed for the patient population that requires treatment in the 3L setting and beyond. This review highlights the need for clear guidelines and new therapies for patients requiring 3L treatment and beyond.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据